Long-term clinical data from Roche strengthen the case for disease-modifying therapies in spinal muscular atrophy and Duchenne muscular …
Long-term clinical data from Roche strengthen the case for disease-modifying therapies in spinal muscular atrophy and Duchenne muscular …
March 2025 is marked by significant deal-making, promising clinical trial results, and innovations across small molecules, biologics, and …
India’s Sun Pharmaceutical Industries strengthens its immuno-oncology capabilities with acquisition of U.S.-based Checkpoint Therapeutics.
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
Long-term data demonstrate that EBGLYSS offers durable skin improvement and symptom relief, reinforcing its role as a first-line …
Investments in next-generation manufacturing facilities are unlocking scale, speed, and quality for cell and gene therapies, propelling North …
Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
Landmark clinical results suggest preventative therapy could delay or halt Alzheimer’s onset in high-risk individuals, reshaping the outlook …
Large funding rounds and strategic partnerships highlight a more focused investment environment, concentrating on companies with late stage …
Already a subscriber? Log in